rs879254820

Positions:

• chr19-11111639-G-A
• chr19-11111639-G-C

Variant summary

Our verdict is Likely pathogenic. Variant got 9 ACMG points: 9P and 0B. PP1_Moderate PM2 PP3 PP4 PS4_Supporting PM3

This summary comes from the ClinGen Evidence Repository: The NM_000527.5 (LDLR):c.1186G>A (p.Gly396Ser) variant is classified as Likely Pathogenic for Familial Hypercholesterolemia by applying evidence codes (PM2, PP3, PP4, PS4_Supporting, PM3, PP1_Moderate) as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (https://doi.org/10.1016/j.gim.2021.09.012).The supporting evidence is as follows:PM2: This variant is absent from gnomAD (gnomAD version 2.1.1).PP3: REVEL=0.774, which is above threshold of 0.75, met PP3, splicing prediction is not required by these guidelines. However, this variant is located at the end of exon 8 within canonical donor motif, and is predicted to affect donor site splicing process in scenario A, donor site: The variant is located at -3 to +6 bases of canonical donor splicing site of exon 8. Wild type canonical donor motif: TGGGTGAGC, MES: 7.23; Variant canonical donor motif: TGAGTGAGC, MES: 3.38. Var/Wt ratio = 0.47 (<0.8), also met PP3.PP4: Variant meets PM2 and is identified in >1 index cases who fulfil FH diagnostic criteria after alternative causes of high cholesterol were excluded.PS4_Supporting: Variant meets PM2 and is identified in 2 unrelated index case who fulfil DLCN criteria for FH diagnosis, one case reported by Koivisto et al, 1995, University of Helsinki, Finland; PMID 7573037; one case reported from Robarts Research Institute, Canada.PM3: This variant meets PM2, and is identified in a HoFH index case (LDLC 14.9 mmol/l at age of 3yrs) and LDLR:c.16_17insTTCCT:p.W6fs (ClinVarID 369864), classified as Pathogenic by these guidelines. Two variants are confirmed in trans, reported from Robarts Research Institute, Canada. PP1_Moderate: Variant segregates with FH phenotype in at least 4 informative meiosis from two families. Three affected family members tested positive for the variant from one family, reported from Robarts Research Institute, Canada. At least 1 co-segregation with hypercholesterolemia was observed from one family, reported by Koivisto et al, 1995, University of Helsinki, Finland; PMID 7573037.BS3 not met: Level 1 assays of whole LDLR cycle performed in LDLR-/- fibroblasts (549T cells) infected with recombinant retroviruses expressing WT LDLR and the variant. Assay results shown cells expressing G396S had no effect on lipoprotein uptake and no defects in receptor distribution, lipoprotein binding, or acid-dependent release, reported by Zhao and Michaely, 2011, Department of Cell Biology at the University of Texas Southwestern Medical Center, US, PMID 21511053. The functional study is not consistent with damaging effect. The experiments did not include splicing mechanism, variant affecting splicing process would not be validated in this study. PM5 not met: Three other missense variants in the same codon: NM_000527.5 (LDLR):c.1186G>C (p.Gly396Arg), (ClinVarID 870321), NM_000527.5 (LDLR):c.1187G>T (p.Gly396Val), (ClinVarID 924165), NM_000527.5 (LDLR):c.1187G>A (p.Gly396Asp), (ClinVarID 440630). None is classified as Pathogenic by these guidelines, therefore PM5 is not met. LINK:https://erepo.genome.network/evrepo/ui/classification/CA10585341/MONDO:0007750/013

• Frequency: Genomes: not found (cov: 31)
• Consequence: LDLR NM_000527.5 missense, splice_region
• Scores: Splicing: ADA: 1.000
• Clinical Significance: Likely pathogenic reviewed by expert panel P:2 U:2
• Conservation: PhyloP100: 4.98

Genes affected

LDLR (HGNC:6547): (low density lipoprotein receptor) The low density lipoprotein receptor (LDLR) gene family consists of cell surface proteins involved in receptor-mediated endocytosis of specific ligands. The encoded protein is normally bound at the cell membrane, where it binds low density lipoprotein/cholesterol and is taken into the cell. Lysosomes release the cholesterol, which is made available for repression of microsomal enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, the rate-limiting step in cholesterol synthesis. At the same time, a reciprocal stimulation of cholesterol ester synthesis takes place. Mutations in this gene cause the autosomal dominant disorder, familial hypercholesterolemia. Alternate splicing results in multiple transcript variants.[provided by RefSeq, May 2022]

LDLR (HGNC:):

ACMG classification

Verdict is Likely_pathogenic. Variant got 9 ACMG points.

• PS4: For more information check the summary or visit ClinGen Evidence Repository.
• PM2: For more information check the summary or visit ClinGen Evidence Repository.
• PM3: For more information check the summary or visit ClinGen Evidence Repository.
• PP1: For more information check the summary or visit ClinGen Evidence Repository.
• PP3: For more information check the summary or visit ClinGen Evidence Repository.
• PP4: For more information check the summary or visit ClinGen Evidence Repository.

Transcripts

RefSeq

Gene	Transcript	HGVSc	HGVSp	Effect	#exon/exons	MANE	Protein	UniProt
LDLR	NM_000527.5	c.1186G>A	p.Gly396Ser	missense_variant, splice_region_variant	8/18	ENST00000558518.6	NP_000518.1

Ensembl

Gene	Transcript	HGVSc	HGVSp	Effect	#exon/exons	TSL	MANE	Protein	Appris	UniProt
LDLR	ENST00000558518.6	c.1186G>A	p.Gly396Ser	missense_variant, splice_region_variant	8/18	1	NM_000527.5	ENSP00000454071.1

Frequencies

GnomAD3 genomes Cov.: 31

GnomAD4 exome Cov.: 32

GnomAD4 genome Cov.: 31

ClinVar

Significance: Likely pathogenic

Submissions summary: Pathogenic:2 Uncertain:2

Revision: reviewed by expert panel

Submissions by phenotype

Hypercholesterolemia, familial, 1 Pathogenic:2 Uncertain:2

Uncertain significance, criteria provided, single submitter	clinical testing	Robarts Research Institute, Western University	Aug 22, 2019	- -
Likely pathogenic, reviewed by expert panel	curation	ClinGen Familial Hypercholesterolemia Variant Curation Expert Panel	Oct 28, 2022	The NM_000527.5 (LDLR):c.1186G>A (p.Gly396Ser) variant is classified as Likely Pathogenic for Familial Hypercholesterolemia by applying evidence codes (PM2, PP3, PP4, PS4_Supporting, PM3, PP1_Moderate) as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (https://doi.org/10.1016/j.gim.2021.09.012). The supporting evidence is as follows: PM2: This variant is absent from gnomAD (gnomAD version 2.1.1). PP3: REVEL=0.774, which is above threshold of 0.75, met PP3, splicing prediction is not required by these guidelines. However, this variant is located at the end of exon 8 within canonical donor motif, and is predicted to affect donor site splicing process in scenario A, donor site: The variant is located at -3 to +6 bases of canonical donor splicing site of exon 8. Wild type canonical donor motif: TGGGTGAGC, MES: 7.23; Variant canonical donor motif: TGAGTGAGC, MES: 3.38. Var/Wt ratio = 0.47 (<0.8), also met PP3. PP4: Variant meets PM2 and is identified in >1 index cases who fulfil FH diagnostic criteria after alternative causes of high cholesterol were excluded. PS4_Supporting: Variant meets PM2 and is identified in 2 unrelated index case who fulfil DLCN criteria for FH diagnosis, one case reported by Koivisto et al, 1995, University of Helsinki, Finland; PMID 7573037; one case reported from Robarts Research Institute, Canada. PM3: This variant meets PM2, and is identified in a HoFH index case (LDLC 14.9 mmol/l at age of 3yrs) and LDLR:c.16_17insTTCCT:p.W6fs (ClinVarID 369864), classified as Pathogenic by these guidelines. Two variants are confirmed in trans, reported from Robarts Research Institute, Canada. PP1_Moderate: Variant segregates with FH phenotype in at least 4 informative meiosis from two families. Three affected family members tested positive for the variant from one family, reported from Robarts Research Institute, Canada. At least 1 co-segregation with hypercholesterolemia was observed from one family, reported by Koivisto et al, 1995, University of Helsinki, Finland; PMID 7573037. BS3 not met: Level 1 assays of whole LDLR cycle performed in LDLR-/- fibroblasts (549T cells) infected with recombinant retroviruses expressing WT LDLR and the variant. Assay results shown cells expressing G396S had no effect on lipoprotein uptake and no defects in receptor distribution, lipoprotein binding, or acid-dependent release, reported by Zhao and Michaely, 2011, Department of Cell Biology at the University of Texas Southwestern Medical Center, US, PMID 21511053. The functional study is not consistent with damaging effect. The experiments did not include splicing mechanism, variant affecting splicing process would not be validated in this study. PM5 not met: Three other missense variants in the same codon: NM_000527.5 (LDLR):c.1186G>C (p.Gly396Arg), (ClinVarID 870321), NM_000527.5 (LDLR):c.1187G>T (p.Gly396Val), (ClinVarID 924165), NM_000527.5 (LDLR):c.1187G>A (p.Gly396Asp), (ClinVarID 440630). None is classified as Pathogenic by these guidelines, therefore PM5 is not met. -
Likely pathogenic, criteria provided, single submitter	literature only	LDLR-LOVD, British Heart Foundation	Mar 25, 2016	- -
Uncertain significance, criteria provided, single submitter	curation;literature only	Cardiovascular Research Group, Instituto Nacional de Saude Doutor Ricardo Jorge	Mar 01, 2016	- -

Computational scores

Source: dbNSFP v4.3

Name	Calibrated prediction	Score	Prediction
AlphaMissense	Benign	0.24
BayesDel_addAF	Pathogenic	0.27	D
BayesDel_noAF	Pathogenic	0.16
CADD	Pathogenic	35
DANN	Uncertain	1.0
DEOGEN2	Pathogenic	0.86	D;.;.;.;.;.
Eigen	Uncertain	0.31
Eigen_PC	Uncertain	0.28
FATHMM_MKL	Pathogenic	0.98	D
LIST_S2	Uncertain	0.94	D;D;D;D;D;D
M_CAP	Pathogenic	0.55	D
MetaRNN	Pathogenic	0.82	D;D;D;D;D;D
MetaSVM	Uncertain	0.68	D
MutationAssessor	Benign	1.6	L;.;.;.;.;L
PrimateAI	Uncertain	0.54	T
PROVEAN	Pathogenic	-5.5	D;D;D;D;D;D
REVEL	Pathogenic	0.77
Sift	Uncertain	0.0030	D;T;D;D;D;D
Sift4G	Uncertain	0.016	D;D;D;D;D;D
Polyphen		0.97	D;.;.;.;.;.
Vest4		0.24
MutPred		0.80		Gain of catalytic residue at G396 (P = 0.0213);Gain of catalytic residue at G396 (P = 0.0213);.;.;.;Gain of catalytic residue at G396 (P = 0.0213);
MVP		1.0
MPC		0.39
ClinPred		0.97	D
GERP RS		4.5
RBP_binding_hub_radar		0.0
RBP_regulation_power_radar		2.8
Varity_R		0.64
gMVP		0.90

Splicing

Name	Calibrated prediction	Score	Prediction
dbscSNV1_ADA	Pathogenic	1.0
dbscSNV1_RF	Pathogenic	1.0
SpliceAI score (max)		0.95		Details are displayed if max score is > 0.2
DS_DG_spliceai		0.95		Position offset: -4
DS_DL_spliceai		0.62		Position offset: 0

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Other links and lift over

dbSNP: rs879254820; hg19: chr19-11222315;